Clinical Trial Update: Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial comparing Arterolane-PQP to DHA-PQP for uncomplicated falciparum malaria in eastern Myanmar has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Falciparum Malaria

Drugs mentioned

• Arterolane-PQP (arterolane; piperaquine phosphate)
• DHA-PQP (dihydroartemisinin; pipuraquine phosphate)

Snippet

Sponsor: University of Oxford | Conditions: Uncomplicated Falciparum Malaria, Artemisinin-resistant | Phase 2, Phase 3 | Status: WITHDRAWN